Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€5.56

€5.56

-3.100%
-0.18
-3.100%
-
 
24.07.26 / Tradegate WKN: A3CRZT / Name: Affluent Medical Sas / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Affluent Medical Sas Stock

Affluent Medical Sas took a tumble today and lost -€0.180 (-3.100%).

Pros and Cons of Affluent Medical Sas in the next few years

Pros
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

News

Carvolix presents promising clinical data on the TAVIPILOT platform at New York Valves 2026
Carvolix presents promising clinical data on the TAVIPILOT platform at New York Valves 2026
Carvolix presents promising clinical data on the TAVIPILOT platform at New York Valves 2026
Carvolix Secures New EUR 10m Tranche, Bringing Total Financing to EUR 20m as Part of its EUR 30m Programme
Carvolix Secures New EUR 10m Tranche, Bringing Total Financing to EUR 20m as Part of its EUR 30m Programme
Carvolix Secures New EUR 10m Tranche, Bringing Total Financing to EUR 20m as Part of its EUR 30m Programme
Carvolix announces positive 3-years clinical results for Kalios™ , the only adjustable mitral ring. 100% of patients met primary endpoint for mitral regurgitation.
Carvolix announces positive 3-years clinical results for Kalios™ , the only adjustable mitral ring. 100% of patients met primary endpoint for mitral regurgitation.
Carvolix announces positive 3-years clinical results for Kalios™ , the only adjustable mitral ring. 100% of patients met primary endpoint for mitral regurgitation.